Pub Date : 2023-08-01Epub Date: 2023-10-04DOI: 10.2217/fvl-2023-0089
Hanie Karimi, Vahid Mansouri, Nima Rezaei
Since 2020, the highly contagious nature and various transmission routes of SARS-CoV-2 have rendered the pandemic interminable. Vertical transmission (VT) through the placenta and breast milk, which is frequent for certain virus types, is thought to exist for SARS-CoV-2 and is hypothesized by many researchers. Conversely, antibodies are produced to counteract the effect of viruses. Since newborns' immunologic system cannot produce proper antibodies, maternal antibodies are usually transferred from mother to infant/fetus to meet the need. This theory leads to the hypothesis of transmission of antibodies through the placenta and breast milk following SARS-CoV-2 infection or vaccination. This paper further discusses these hypotheses, considering consequences of fetus/infant harm versus benefit.
{"title":"Vertical transmission and maternal passive immunity post-SARS-CoV-2.","authors":"Hanie Karimi, Vahid Mansouri, Nima Rezaei","doi":"10.2217/fvl-2023-0089","DOIUrl":"10.2217/fvl-2023-0089","url":null,"abstract":"<p><p>Since 2020, the highly contagious nature and various transmission routes of SARS-CoV-2 have rendered the pandemic interminable. Vertical transmission (VT) through the placenta and breast milk, which is frequent for certain virus types, is thought to exist for SARS-CoV-2 and is hypothesized by many researchers. Conversely, antibodies are produced to counteract the effect of viruses. Since newborns' immunologic system cannot produce proper antibodies, maternal antibodies are usually transferred from mother to infant/fetus to meet the need. This theory leads to the hypothesis of transmission of antibodies through the placenta and breast milk following SARS-CoV-2 infection or vaccination. This paper further discusses these hypotheses, considering consequences of fetus/infant harm versus benefit.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564388/pdf/fvl-2023-0089.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41197546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mona Fani, Maryam Moossavi, Hasan Bakhshi, Abozar Nasiri Jahrodi, Mohammad Reza Khazdair, Amir Hossein Zardast, Shokouh Ghafari
Despite passing the pandemic phase of the COVID-19, researchers are still investigating various drugs. Previous evidence suggests that blocking the calcium channels may be a suitable treatment option. Ca2+ is required to enhance the fusion process of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Also, some important inflammatory factors during SARS-CoV-2 infection are dependent on Ca2+ level. On the other hand, viroporins have emerged as attractive targets for antiviral therapy due to their essential role in viral replication and pathogenesis. By inhibiting the host calcium channels and viroporins, it is possible to limit the spread of infection. Therefore, calcium channel blockers (CCBs) and drugs targeting Viroporins can be considered an effective option in the fight against SARS-CoV-2.
{"title":"Targeting host calcium channels and viroporins: a promising strategy for SARS-CoV-2 therapy.","authors":"Mona Fani, Maryam Moossavi, Hasan Bakhshi, Abozar Nasiri Jahrodi, Mohammad Reza Khazdair, Amir Hossein Zardast, Shokouh Ghafari","doi":"10.2217/fvl-2022-0203","DOIUrl":"https://doi.org/10.2217/fvl-2022-0203","url":null,"abstract":"<p><p>Despite passing the pandemic phase of the COVID-19, researchers are still investigating various drugs. Previous evidence suggests that blocking the calcium channels may be a suitable treatment option. Ca<sup>2+</sup> is required to enhance the fusion process of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Also, some important inflammatory factors during SARS-CoV-2 infection are dependent on Ca<sup>2+</sup> level. On the other hand, viroporins have emerged as attractive targets for antiviral therapy due to their essential role in viral replication and pathogenesis. By inhibiting the host calcium channels and viroporins, it is possible to limit the spread of infection. Therefore, calcium channel blockers (CCBs) and drugs targeting Viroporins can be considered an effective option in the fight against SARS-CoV-2.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10229899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: A triple epidemic of respiratory syncytial virus (RSV), SARS-CoV-2 and influenza variants is on the rise worldwide. It is crucial to identify antiviral agents that can be used against all three viruses associatd with this triple epidemic. Materials & methods: A total of ten antiviral agents were investigated in this study. Using molecular docking and the molecular mechanics/position-Boltzmann surface area technique, an examination of the binding affinity and protein–ligand interactions was conducted. Results: Out of the ten ligands that were compared, three showed the highest affinity for the docking site related to three the viral infections in descending order: AVG-388, remdesivir and nirmatrelvir. Conclusion: In conclusion, AVG-388, remdesivir and nirmatrelvir could be recommended as effective antiviral agents during the triple epidemic.
{"title":"A single antiviral for a triple epidemic: is it possible?","authors":"N. Sultanoglu, E. Erdag, Cenk Serhan Ozverel","doi":"10.2217/fvl-2023-0048","DOIUrl":"https://doi.org/10.2217/fvl-2023-0048","url":null,"abstract":"Aim: A triple epidemic of respiratory syncytial virus (RSV), SARS-CoV-2 and influenza variants is on the rise worldwide. It is crucial to identify antiviral agents that can be used against all three viruses associatd with this triple epidemic. Materials & methods: A total of ten antiviral agents were investigated in this study. Using molecular docking and the molecular mechanics/position-Boltzmann surface area technique, an examination of the binding affinity and protein–ligand interactions was conducted. Results: Out of the ten ligands that were compared, three showed the highest affinity for the docking site related to three the viral infections in descending order: AVG-388, remdesivir and nirmatrelvir. Conclusion: In conclusion, AVG-388, remdesivir and nirmatrelvir could be recommended as effective antiviral agents during the triple epidemic.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43237885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jing Chen, Guoyun Su, Ruimu Zhang, Jikui Deng, Lifeng Qi
Aim: This study aimed to identify potential plasma biomarkers for severe pediatric adenovirus (AdV) infection. Methods: Thirty-seven inflammatory proteins were measured in the plasma of AdV-infected, influenza H3N2-infected or healthy pediatric participants and the prediction values of selected inflammatory proteins for AdV and severe AdV were assessed. Results: The expression profiles of AdV- and H3N2-infected patients were largely similar, with only IL-2, IL-10, IL-19 and IL-32 showing pathogen-dependent expression. IL-10, IL-19 and IL-32, both individually and in combination, could predict AdV and severe AdV infection. Conclusion: Plasma IL-10, IL-19 and IL-32 are potential biomarkers for AdV, especially severe AdV in pediatric patients.
{"title":"Plasma IL-10, IL-19 and IL-32 are potential biomarkers for adenovirus-induced severe pneumonia in pediatric patients","authors":"Jing Chen, Guoyun Su, Ruimu Zhang, Jikui Deng, Lifeng Qi","doi":"10.2217/fvl-2023-0080","DOIUrl":"https://doi.org/10.2217/fvl-2023-0080","url":null,"abstract":"Aim: This study aimed to identify potential plasma biomarkers for severe pediatric adenovirus (AdV) infection. Methods: Thirty-seven inflammatory proteins were measured in the plasma of AdV-infected, influenza H3N2-infected or healthy pediatric participants and the prediction values of selected inflammatory proteins for AdV and severe AdV were assessed. Results: The expression profiles of AdV- and H3N2-infected patients were largely similar, with only IL-2, IL-10, IL-19 and IL-32 showing pathogen-dependent expression. IL-10, IL-19 and IL-32, both individually and in combination, could predict AdV and severe AdV infection. Conclusion: Plasma IL-10, IL-19 and IL-32 are potential biomarkers for AdV, especially severe AdV in pediatric patients.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45568855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Aljabali, Mohammad A. Obeid, Mohamed El-Tanani, M. Tambuwala
Respiratory syncytial virus (RSV) is a leading cause of respiratory illnesses that primarily affects children, particularly those under 2 years old, and adults. RSV infections can lead to hospitalization and even mortality. The virus is transmitted through respiratory droplets spread by coughing or sneezing. We conducted an extensive literature search focused on RSV, pathogenicity and relevant keywords like ‘RSV treatment,’ ‘RSV vaccine,‘ and ‘RSV diagnosis’ to explore effective treatment strategies, advances in potential RSV vaccines and ongoing clinical trials, and progress in diagnostic techniques for accurate and timely detection of RSV infections. These findings are crucial for developing appropriate management and control measures.
{"title":"Respiratory syncytial virus: an overview","authors":"A. Aljabali, Mohammad A. Obeid, Mohamed El-Tanani, M. Tambuwala","doi":"10.2217/fvl-2023-0037","DOIUrl":"https://doi.org/10.2217/fvl-2023-0037","url":null,"abstract":"Respiratory syncytial virus (RSV) is a leading cause of respiratory illnesses that primarily affects children, particularly those under 2 years old, and adults. RSV infections can lead to hospitalization and even mortality. The virus is transmitted through respiratory droplets spread by coughing or sneezing. We conducted an extensive literature search focused on RSV, pathogenicity and relevant keywords like ‘RSV treatment,’ ‘RSV vaccine,‘ and ‘RSV diagnosis’ to explore effective treatment strategies, advances in potential RSV vaccines and ongoing clinical trials, and progress in diagnostic techniques for accurate and timely detection of RSV infections. These findings are crucial for developing appropriate management and control measures.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43521683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Creech, E. Anderson, V. Berthaud, Í. Yildirim, AM Atz, I. M. Baez, D. Finkelstein, P. Pickrell, J. Kirstein, C. Yut, R. Blair, RA Clifford, M. Dunn, JD Campbell, D. Montefiori, JE Tomassini, X. Zhao, W. Deng, H. Zhou, D. Schrempp, K. Hautzinger, B. Girard, K. Slobod, R. McPhee, R. Pajon, R. Das, Jm Miller, S. S. Ghamloush
The PLSP summarizes results from the phase 2/3 KidCOVE trial examining mRNA-1273 (Moderna's COVID-19 vaccine) in children 6 through 11 years of age. This study reviewed results from two parts of the KidCOVE clinical trial: Part 1 of the study was performed to select a dose of mRNA-1273 (50 μg or 100 μg) in children. A 50-μg dose was selected for further evaluation based on minimally unwanted side effects and sufficient antibodies (immune responses) against SARS-CoV-2. Part 2 of the study further evaluated the 50-μg dose of mRNA-1273 and compared it with placebo in children. Two 50-μg doses of mRNA-1273 were well tolerated with no new safety concerns. Two 50-μg doses also produced antibodies (immune responses) similar to those in young adults who received mRNA-1273 (100 μg) in a separate phase 3 study (the COVE trial). Study findings suggest that two 50-μg doses of mRNA-1273 were well-tolerated, and can prevent COVID-19 in children 6 through 11 years of age. Clinical Trial Registration: NCT04796896 ( ClinicalTrials.gov )
{"title":"Plain Language Summary of a Clinical Trial Evaluating mRNA-1273, Moderna's mRNA-Based COVID-19 Vaccine, in Children 6 Through 11 Years of Age","authors":"C. Creech, E. Anderson, V. Berthaud, Í. Yildirim, AM Atz, I. M. Baez, D. Finkelstein, P. Pickrell, J. Kirstein, C. Yut, R. Blair, RA Clifford, M. Dunn, JD Campbell, D. Montefiori, JE Tomassini, X. Zhao, W. Deng, H. Zhou, D. Schrempp, K. Hautzinger, B. Girard, K. Slobod, R. McPhee, R. Pajon, R. Das, Jm Miller, S. S. Ghamloush","doi":"10.2217/fvl-2023-0020","DOIUrl":"https://doi.org/10.2217/fvl-2023-0020","url":null,"abstract":"The PLSP summarizes results from the phase 2/3 KidCOVE trial examining mRNA-1273 (Moderna's COVID-19 vaccine) in children 6 through 11 years of age. This study reviewed results from two parts of the KidCOVE clinical trial: Part 1 of the study was performed to select a dose of mRNA-1273 (50 μg or 100 μg) in children. A 50-μg dose was selected for further evaluation based on minimally unwanted side effects and sufficient antibodies (immune responses) against SARS-CoV-2. Part 2 of the study further evaluated the 50-μg dose of mRNA-1273 and compared it with placebo in children. Two 50-μg doses of mRNA-1273 were well tolerated with no new safety concerns. Two 50-μg doses also produced antibodies (immune responses) similar to those in young adults who received mRNA-1273 (100 μg) in a separate phase 3 study (the COVE trial). Study findings suggest that two 50-μg doses of mRNA-1273 were well-tolerated, and can prevent COVID-19 in children 6 through 11 years of age. Clinical Trial Registration: NCT04796896 ( ClinicalTrials.gov )","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48170881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Asma Bouazizi, Mouna Ben Hadj Fredj, A. Jerbi, Haifa Bennour, I. Fodha, A. Trabelsi
Aim: To evaluate human adenovirus (HAdV) types associated with respiratory infections, nasopharyngeal aspirations (NPA) were collected from children under 2 years old that were hospitalized for acute respiratory tract infections (ARTI) during 2018–2019. Methods: PCR was used for viral screening and select samples were then sequenced by Sanger sequencing. Results: Among 194 samples, 30 were HAdV-positive and 14 were chosen for further sequencing. HAdV-F41, C2 and C5 circulated simultaneously with an unexpected predominance of HAdV-F41. HAdV infection occurred year-round, with a peak in winter and early spring. The age group most affected was those younger than 6 months. Conclusion: Continued surveillance of HAdV infections is necessary and the contribution of HAdV-F41 in ARTI should be studied.
{"title":"Unexpected predominance of human adenovirus F41 in children suffering from acute respiratory infection in Tunisia","authors":"Asma Bouazizi, Mouna Ben Hadj Fredj, A. Jerbi, Haifa Bennour, I. Fodha, A. Trabelsi","doi":"10.2217/fvl-2022-0215","DOIUrl":"https://doi.org/10.2217/fvl-2022-0215","url":null,"abstract":"Aim: To evaluate human adenovirus (HAdV) types associated with respiratory infections, nasopharyngeal aspirations (NPA) were collected from children under 2 years old that were hospitalized for acute respiratory tract infections (ARTI) during 2018–2019. Methods: PCR was used for viral screening and select samples were then sequenced by Sanger sequencing. Results: Among 194 samples, 30 were HAdV-positive and 14 were chosen for further sequencing. HAdV-F41, C2 and C5 circulated simultaneously with an unexpected predominance of HAdV-F41. HAdV infection occurred year-round, with a peak in winter and early spring. The age group most affected was those younger than 6 months. Conclusion: Continued surveillance of HAdV infections is necessary and the contribution of HAdV-F41 in ARTI should be studied.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44313358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Igarashi, K. Togo, Yasuhiro Kobayashi, Kazumasa Kamei, N. Yonemoto, N. Ishiwada
Objective: To evaluate healthcare resource use for respiratory syncytial virus (RSV) in Japan. Methods: Using JMDC and Medical Data Vision (MDV) claims databases, we retrospectively evaluated cost and length of hospital/intensive care unit stays in RSV-diagnosed cohorts of infants (<12 months) and older adults (OAs, ≥60 years). We analyzed the usage and costs of palivizumab in infants. Results: Mean costs among those hospitalized were $2823 (USD); $2851; and $6609 (¥131 [JPY]/$) in JMDC-infant (n = 13,752); MDV-infant (n = 22,142); and MDV-OA cohorts (n = 165), respectively. The mean cost was higher in those aged <1 month, with risk factors, and severe RSV disease. Mean cumulative cost of palivizumab prophylaxis in JMDC infant cohort was $6796/year. Conclusion: RSV causes enormous economic burden in infants and OAs.
{"title":"Inpatient and outpatient costs associated with respiratory syncytial virus in Japanese infants and older adults","authors":"A. Igarashi, K. Togo, Yasuhiro Kobayashi, Kazumasa Kamei, N. Yonemoto, N. Ishiwada","doi":"10.2217/fvl-2023-0069","DOIUrl":"https://doi.org/10.2217/fvl-2023-0069","url":null,"abstract":"Objective: To evaluate healthcare resource use for respiratory syncytial virus (RSV) in Japan. Methods: Using JMDC and Medical Data Vision (MDV) claims databases, we retrospectively evaluated cost and length of hospital/intensive care unit stays in RSV-diagnosed cohorts of infants (<12 months) and older adults (OAs, ≥60 years). We analyzed the usage and costs of palivizumab in infants. Results: Mean costs among those hospitalized were $2823 (USD); $2851; and $6609 (¥131 [JPY]/$) in JMDC-infant (n = 13,752); MDV-infant (n = 22,142); and MDV-OA cohorts (n = 165), respectively. The mean cost was higher in those aged <1 month, with risk factors, and severe RSV disease. Mean cumulative cost of palivizumab prophylaxis in JMDC infant cohort was $6796/year. Conclusion: RSV causes enormous economic burden in infants and OAs.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42605802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: This study aimed to present the characteristics and poor prognostic factors of Crimean–Congo hemorrhagic fever (CCHF) patients. Materials & methods: Adult patients (>18 years) with CCHF were included in this retrospective study. Demographics, risk scores and laboratory findings of survivors and nonsurvivors were compared. Results: Fifteen (9.2%) of 163 CCHF patients were nonsurvivors and had a higher Severity Score Index (p < 0.001), Severity Grade Score (p < 0.001) and De Ritis ratio (aspartate transaminase/alanine transaminase) (p < 0.001). De Ritis ratio was >3 in 10.1% of survivors and 53.3% of nonsurvivors (p < 0.001). In multivariate analysis, De Ritis ratio >3 (OR: 5.428, p = 0.045) and SGS (OR: 1.776, p = 0.005) were found as predictive factors. Conclusion: De Ritis ratio may predict prognosis in combination with severity risk scores in CCHF.
目的:探讨克里米亚-刚果出血热(CCHF)患者的特点及影响预后的因素。材料与方法:本回顾性研究纳入成年CCHF患者(bb0 ~ 18岁)。对幸存者和非幸存者的人口统计、风险评分和实验室结果进行比较。结果:163例CCHF患者中有15例(9.2%)为非幸存者，严重程度评分指数(severe Score Index)较高(10.1%的幸存者为3,53.3%的非幸存者为3 (p = 5.428, p = 0.045)和SGS (OR: 1.776, p = 0.005)为预测因素。结论:De - Ritis比值可与CCHF严重危险评分联合预测预后。
{"title":"The association of De Ritis ratio with the severity of Crimean–Congo hemorrhagic fever","authors":"Esma Eryilmaz-Eren, Ayse Turunc-Ozdemir, Azade Kanat, Zeynep Ture, Ayşin Kılınç-Toker, I. Çelik","doi":"10.2217/fvl-2023-0008","DOIUrl":"https://doi.org/10.2217/fvl-2023-0008","url":null,"abstract":"Aim: This study aimed to present the characteristics and poor prognostic factors of Crimean–Congo hemorrhagic fever (CCHF) patients. Materials & methods: Adult patients (>18 years) with CCHF were included in this retrospective study. Demographics, risk scores and laboratory findings of survivors and nonsurvivors were compared. Results: Fifteen (9.2%) of 163 CCHF patients were nonsurvivors and had a higher Severity Score Index (p < 0.001), Severity Grade Score (p < 0.001) and De Ritis ratio (aspartate transaminase/alanine transaminase) (p < 0.001). De Ritis ratio was >3 in 10.1% of survivors and 53.3% of nonsurvivors (p < 0.001). In multivariate analysis, De Ritis ratio >3 (OR: 5.428, p = 0.045) and SGS (OR: 1.776, p = 0.005) were found as predictive factors. Conclusion: De Ritis ratio may predict prognosis in combination with severity risk scores in CCHF.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48785601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号